Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069245 | 0.83 | CDC25A (0.52) | CDC25ACDC25BVDRNR1H4CYP24A1 | |
| SCHEMBL13853984 | 0.78 | CDC25A (0.50) | CDC25ACDC25BUSP2VDRNR1H4 | |
| SCHEMBL13392661 | 0.78 | CDC25A (0.50) | CDC25ACDC25BUSP2VDR | |
| SCHEMBL4180944 | 0.78 | CDC25A (0.50) | CDC25ACDC25BUSP2VDR | |
| SCHEMBL6830893 | 0.78 | CDC25A (0.50) | CDC25ACDC25BUSP2VDR | |
| SCHEMBL8502677 | 0.76 | CDC25A (0.48) | CDC25ACDC25BUSP2VDRNR1H4 | |
| SCHEMBL6690597 | 0.76 | CDC25A (0.48) | CDC25ACDC25BUSP2VDRNR1H4 | |
| SCHEMBL10019058 | 0.75 | SRD5A2 (0.44) | CDC25ACDC25B | |
| SCHEMBL12634971 | 0.75 | SRD5A2 (0.44) | CDC25ACDC25B | |
| SCHEMBL12634972 | 0.75 | SRD5A2 (0.44) | CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061070-B1 | Process for the preparation of ED-71 | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-6538145-B2 | Having a hydroxy group at 24-position and, optionally, a substituent at 2 beta position; reacting intermediates of the A ring part and intermediates of the C ring; cyclization; coupling; control of calcium metabolism; antitumor agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-18 | — | — | US | disclosed |
| EP-1061070-A1 | 24-HYDROXYVITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CYP24A1, VDR, CYP2R1 | CDC25A 1723/4885CDC25B 2256/4885USP2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.